EMA Authorised: Akynzeo (netupitant;palonosetron hydrochloride) — Helsinn Birex Pharmaceuticals Ltd

View source ↗

Summary

EMA authorised Akynzeo, a fixed-dose combination of netupitant and palonosetron hydrochloride, for prevention of vomiting and nausea associated with cancer chem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Akynzeo (netupitant/palonosetron)

Snippet

Status: Authorised. Therapeutic area: Vomiting;Neoplasms;Nausea;Cancer. MAH: Helsinn Birex Pharmaceuticals Ltd. Decision date: 12/02/2026